MediciNova looks to ride NASH wave with Phase II start
This article was originally published in Scrip
Executive Summary
The US venture MediciNova is apparently attempting to make the most of recent investor and medical interest in non-alcoholic steatohepatitis (NASH) therapies by announcing plans to start clinical trials in this indication for one of its dormant pipeline molecules.